AVALO THERAPEUTICS, INC. Deferred Tax Liabilities, Leasing Arrangements
AVALO THERAPEUTICS, INC. (AVTX) had Deferred Tax Liabilities, Leasing Arrangements of $286.00 thousand as of 2023-12-31, per its 10-K filed 2024-03-29.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities
us-gaap:DeferredTaxLiabilitiesLeasingArrangements · last filed 2024-03-29
- 2023-12-31: Deferred Tax Liabilities, Leasing Arrangements $286.00K.
- 2022-12-31: Deferred Tax Liabilities, Leasing Arrangements $408.00K.
- 2021-12-31: Deferred Tax Liabilities, Leasing Arrangements $472.00K.
- 2020-12-31: Deferred Tax Liabilities, Leasing Arrangements $224.00K; Deferred Tax Liabilities, Leasing Arrangements as first filed $224.27K.
| Period end | Deferred Tax Liabilities, Leasing Arrangements | Deferred Tax Liabilities, Leasing Arrangements as first filed |
|---|---|---|
| 2023-12-31 | $286.00K 10-K · filed 2024-03-29 | |
| 2022-12-31 | $408.00K 10-K · filed 2024-03-29 | |
| 2021-12-31 | $472.00K 10-K · filed 2023-03-29 | |
| 2020-12-31 | $224.00K 10-K · filed 2022-03-02 | $224.27K 10-K · filed 2021-03-08 |
| 2019-12-31 | $167.94K 10-K · filed 2021-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |